CXCR7 as a novel therapeutic target for advanced prostate cancer

[1]  H. E. Meyer zu Schwabedissen,et al.  Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data , 2022, Frontiers in Pharmacology.

[2]  F. Balkwill,et al.  Harnessing cytokines and chemokines for cancer therapy , 2022, Nature Reviews Clinical Oncology.

[3]  Jeremy C. Smith,et al.  A model for the signal initiation complex between Arrestin-3 and the Src family kinase Fgr. , 2021, Journal of molecular biology.

[4]  Yong Luo,et al.  Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients , 2021, Disease markers.

[5]  K. Welén,et al.  The roles of RUNX2 and osteoclasts in regulating expression of steroidogenic enzymes in castration-resistant prostate cancer cells , 2021, Molecular and Cellular Endocrinology.

[6]  H. Vischer,et al.  Differential Involvement of ACKR3 C-Tail in β-Arrestin Recruitment, Trafficking and Internalization , 2021, Cells.

[7]  G. Alexander,et al.  Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. , 2021, JAMA oncology.

[8]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[9]  F. Lehembre,et al.  Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239. , 2020, Journal of medicinal chemistry.

[10]  R. Lefkowitz,et al.  Allosteric activation of proto-oncogene kinase Src by GPCR–beta-arrestin complexes , 2020, The Journal of Biological Chemistry.

[11]  W. Ricke,et al.  Development and prevalence of castration-resistant prostate cancer subtypes , 2020, Neoplasia.

[12]  Navnath S. Gavande,et al.  Pro-inflammatory cytokines and chemokines initiate multiple prostate cancer biologic pathways of cellular proliferation, heterogeneity and metastasis in a racially diverse population and underlie the genetic/biologic mechanism of racial disparity: Update. , 2020, Urologic oncology.

[13]  H. Park,et al.  CXCR7: a β-arrestin-biased receptor that potentiates cell migration and recruits β-arrestin2 exclusively through Gβγ subunits and GRK2 , 2020, Cell & bioscience.

[14]  P. Loria,et al.  Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel β-Arrestin Antagonist Activity. , 2020, ACS medicinal chemistry letters.

[15]  A. Vetuschi,et al.  Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth , 2019, Cells.

[16]  O. Elemento,et al.  Clinical features of neuroendocrine prostate cancer. , 2019, European journal of cancer.

[17]  I. D. de Esch,et al.  Modulators of CXCR4 and CXCR7/ACKR3 Function , 2019, Molecular Pharmacology.

[18]  Wanhai Xu,et al.  RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis , 2019, Theranostics.

[19]  Ximing J. Yang,et al.  Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. , 2019, Cancer research.

[20]  Kwok-Kin Wong,et al.  CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC. , 2019, Cancer research.

[21]  X. Liu,et al.  Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer , 2018, Molecular Cancer Research.

[22]  F. Scholtes,et al.  Aurora A plays a dual role in migration and survival of human glioblastoma cells according to the CXCL12 concentration , 2018, Oncogene.

[23]  E. Butcher,et al.  A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Bin Zhou,et al.  IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma , 2018, Oncogene.

[25]  K. Pienta,et al.  CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. , 2018, Cancer research.

[26]  Yundong He,et al.  PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer , 2017, Clinical Cancer Research.

[27]  J. Blando,et al.  Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice. , 2017, Cancer research.

[28]  J. Qin,et al.  HIC1 loss promotes prostate cancer metastasis by triggering epithelial–mesenchymal transition , 2017, The Journal of pathology.

[29]  B. Lokeshwar,et al.  Inhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival , 2017, Scientific Reports.

[30]  R. Abagyan,et al.  Structural basis of ligand interaction with atypical chemokine receptor 3 , 2017, Nature Communications.

[31]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[32]  R. Singh,et al.  β-Arrestin-2 Counters CXCR7-Mediated EGFR Transactivation and Proliferation , 2016, Molecular Cancer Research.

[33]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[34]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[35]  J. Bernhagen,et al.  MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP‐70 signaling, and lymphocyte chemotaxis , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  J. Trimmer,et al.  Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility , 2015, BMC Cancer.

[37]  K. Walter,et al.  Targeting chemokine receptor CXCR7 inhibits glioma cell proliferation and mobility. , 2015, Anticancer research.

[38]  M. Jordá,et al.  The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation , 2014, Molecular Cancer.

[39]  Pier Luigi Fiori,et al.  Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses , 2014, Proceedings of the National Academy of Sciences.

[40]  D. Wong,et al.  Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis , 2014, BMC Urology.

[41]  K. Shilo,et al.  C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment , 2014, Breast Cancer Research.

[42]  G. V. van Dongen,et al.  Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growth in Vivo , 2013, The Journal of Biological Chemistry.

[43]  H. Ehrlich,et al.  Human Anti-Macrophage Migration Inhibitory Factor Antibodies Inhibit Growth of Human Prostate Cancer Cells In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[44]  F. Pakdel,et al.  Estrogen represses CXCR7 gene expression by inhibiting the recruitment of NFκB transcription factor at the CXCR7 promoter in breast cancer cells. , 2013, Biochemical and biophysical research communications.

[45]  J. Haefliger,et al.  Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. , 2013, Endocrine-related cancer.

[46]  Xiumin Wang,et al.  Hic1 Modulates Prostate Cancer Progression by Epigenetic Modification No Potential Conflicts of Interest Were Disclosed Statement of Translational Relevance , 2022 .

[47]  D. Templeton,et al.  Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment , 2012, The Journal of Immunology.

[48]  E. Raz,et al.  β-arrestin control of late endosomal sorting facilitates decoy receptor function and chemokine gradient formation , 2012, Development.

[49]  S. Schulz,et al.  Rapid Uptake and Degradation of CXCL12 Depend on CXCR7 Carboxyl-terminal Serine/Threonine Residues* , 2012, The Journal of Biological Chemistry.

[50]  G. Luker,et al.  Carboxy-terminus of CXCR7 regulates receptor localization and function. , 2012, The international journal of biochemistry & cell biology.

[51]  S. Takayama,et al.  Secreted CXCL12 (SDF-1) forms dimers under physiological conditions. , 2012, The Biochemical journal.

[52]  T. Kaoud,et al.  Non‐visual arrestins function as simple scaffolds assembling the MKK4–JNK3a2 signaling complex , 2011, Biochemistry.

[53]  T. Sakmar,et al.  CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration* , 2011, The Journal of Biological Chemistry.

[54]  R. Singh,et al.  Molecular and Cellular Pathobiology The IL-8 – Regulated Chemokine Receptor CXCR 7 Stimulates EGFR Signaling to Promote Prostate Cancer Growth , 2011 .

[55]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[56]  D. Srivastava,et al.  The chemokine receptor CXCR7 functions to regulate cardiac valve remodeling , 2011, Developmental dynamics : an official publication of the American Association of Anatomists.

[57]  M. Ratajczak,et al.  Overlapping and distinct role of CXCR7‐SDF‐1/ITAC and CXCR4‐SDF‐1 axes in regulating metastatic behavior of human rhabdomyosarcomas , 2010, International journal of cancer.

[58]  M. Ratajczak,et al.  Macrophage Migration Inhibitory Factor Is Secreted by Rhabdomyosarcoma Cells, Modulates Tumor Metastasis by Binding to CXCR4 and CXCR7 Receptors and Inhibits Recruitment of Cancer-Associated Fibroblasts , 2010, Molecular Cancer Research.

[59]  G. Luker,et al.  Constitutive and Chemokine-dependent Internalization and Recycling of CXCR7 in Breast Cancer Cells to Degrade Chemokine Ligands , 2010, Oncogene.

[60]  Y. Na,et al.  Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer , 2010, Oncogene.

[61]  B. Adams.  Faculty Opinions recommendation of Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. , 2010 .

[62]  R. Lefkowitz,et al.  β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7 , 2009, Proceedings of the National Academy of Sciences.

[63]  T. Schall,et al.  Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands , 2009, The Journal of Immunology.

[64]  D. Stephan,et al.  Scavenger Chemokine (CXC Motif) Receptor 7 (CXCR7) Is a Direct Target Gene of HIC1 (Hypermethylated in Cancer 1)* , 2009, The Journal of Biological Chemistry.

[65]  F. Baleux,et al.  CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. , 2009, Blood.

[66]  H. Fu,et al.  How Does Arrestin Assemble MAPKs into a Signaling Complex?* , 2009, Journal of Biological Chemistry.

[67]  D. Wong,et al.  Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside , 2008, Clinical Cancer Research.

[68]  K. Pienta,et al.  CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12 , 2008, Clinical & Experimental Metastasis.

[69]  Chun Guo,et al.  The β-Arrestin-2 Scaffold Protein Promotes c-Jun N-terminal Kinase-3 Activation by Binding to Its Nonconserved N Terminus* , 2008, Journal of Biological Chemistry.

[70]  M. Parmentier,et al.  Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. , 2007, Blood.

[71]  Vítězslav Bryja,et al.  β-Arrestin is a necessary component of Wnt/β-catenin signaling in vitro and in vivo , 2007, Proceedings of the National Academy of Sciences.

[72]  K. Iczkowski,et al.  Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells1 , 2006, The Journal of Immunology.

[73]  Kevin Wei,et al.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development , 2006, The Journal of experimental medicine.

[74]  Xiyun Deng,et al.  CXCL12/CXCR4 signaling activates Akt‐1 and MMP‐9 expression in prostate cancer cells: The role of bone microenvironment‐associated CXCL12 , 2006, The Prostate.

[75]  A. Abdel‐Mageed,et al.  Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. , 2005, Cancer research.

[76]  M. Thelen,et al.  The Chemokine SDF-1/CXCL12 Binds to and Signals through the Orphan Receptor RDC1 in T Lymphocytes* , 2005, Journal of Biological Chemistry.

[77]  K. Iczkowski,et al.  Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer , 2005, BMC Cancer.

[78]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[79]  Abraham Schneider,et al.  Skeletal Localization and Neutralization of the SDF‐1(CXCL12)/CXCR4 Axis Blocks Prostate Cancer Metastasis and Growth in Osseous Sites In Vivo , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[80]  Rob Leurs,et al.  CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. , 2003, Blood.

[81]  K. Pienta,et al.  Expression of CXCR4 and CXCL12 (SDF‐1) in human prostate cancers (PCa) in vivo , 2003, Journal of cellular biochemistry.

[82]  Evan T Keller,et al.  Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. , 2002, Cancer research.

[83]  J. Sebolt-Leopold.  Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.

[84]  S. Bodin,et al.  [Expression of a new family of receptors similar to CXC chemokine receptors in endothelial cell precursors]. , 1999, Pathologie-biologie.

[85]  James G. Boyd,et al.  Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.

[86]  J Downward,et al.  PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. , 1997, Trends in biochemical sciences.

[87]  T. Springer,et al.  A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) , 1996, The Journal of experimental medicine.

[88]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[89]  K. Tracey,et al.  MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia , 1993, Nature.

[90]  H. Bartfeld,et al.  Activity and properties of macrophage migration inhibitory factor produced by mixed lymphocyte cultures. , 1971, Nature: New biology.